A Bad Fit: Dan Leonard’s Leadership Style Did Not Translate At AAM
Former employees at the Association for Accessible Medicines detail problems that emerged during Leonard’s tenure, but also say the board of directors must improve its management of the trade organization.
You may also be interested in...
What Does Teva’s Exit From PhRMA Suggest About Its Priorities?
Seemingly in one of the first decisions overseen by the company’s new CEO Richard Francis, Teva will not sit at the table of the US brand industry trade association, the Pharmaceutical Research and Manufacturers of America, better known as PhRMA.
Generic Policy Tweaks In Omnibus Legislation Include Processes Improvements On Late-Stage Label Changes, 505(b)(2) TE Designations
FDA will be able to approve some interchangeable biosimilars more smoothly, but won’t be instructed to provide ANDA sponsors with more information on the inactive ingredients in brand drugs.
Leonard Resignation Leaves AAM Looking For New Leadership
Dan Leonard has announced his resignation as president and CEO of the US Association for Accessible Medicines. He will be replaced on an interim basis by the group’s vice president for sciences and regulatory affairs, David Gaugh.